Showing 1671-1680 of 20875 results for "".
- NICE Recommends First Topical JAK Inhibitor for CHE in England and Waleshttps://reachmd.com/news/nice-recommends-first-topical-jak-inhibitor-for-che-in-england-and-wales/2484333/The National Institute for Health and Care Excellence (NICE) has recommended the reimbursement of Anzupgo® (delgocitinib) cream for adult patients with moderate to severe chronic hand eczema (CHE) who have not responded to,
- Cardiovascular Protection Beyond Weight Loss: Insights from the SELECT Trial on Semaglutidehttps://reachmd.com/news/cardiovascular-protection-beyond-weight-loss-insights-from-the-select-trial-on-semaglutide/2484313/The SELECT trial found that semaglutide reduced major adverse cardiovascular events (MACE) independent of weight loss, suggesting a cardioprotective ef
- Enhanced Glycemic Management in Pregnancy: The Role of Closed-Loop Insulin Systemshttps://reachmd.com/news/enhanced-glycemic-management-in-pregnancy-the-role-of-closed-loop-insulin-systems/2484320/A multicenter trial demonstrated that automated closed-loop insulin therapy substantially increased the percentage of time pre
- Family-Recorded Messages: A New Frontier in ICU Delirium Managementhttps://reachmd.com/news/family-recorded-messages-a-new-frontier-in-icu-delirium-management/2484314/Family-recorded messages increased delirium-free days in mechanically ventilated ICU patients versus standard care in a randomized
- Beyond the Impact: New Insights into CTE and Contact Sport Safetyhttps://reachmd.com/news/beyond-the-impact-new-insights-into-cte-and-contact-sport-safety/2484271/Single‑cell genomic studies now implicate somatic neuronal mutations and persistent immune activation — not just repetitive head impacts — in chronic traumatic encephalopathy (CTE), a
- Incyte Opens Applications for HS-Focused Ingenuity Awardshttps://reachmd.com/news/incyte-opens-applications-for-hs-focused-ingenuity-awards/2484308/Incyte has announced the launch of the Incyte Ingenuity Awards (IIA) in Hidradenitis Suppurativa (HS), a new initiative developed in collaboration with patients, advocates, and clinicians to address challenges faced by HS patients, according to a press release from
- InMode Appoints Michael Dennison as President of North Americahttps://reachmd.com/news/inmode-appoints-michael-dennison-as-president-of-north-america/2484275/InMode Ltd has promoted Michael Dennison to president of North America, the company announced. Dennison previously served as vice president of sales. Dennison joined InMode nearly a decade ago and has held multiple leadership r
- Mediterranean Diet and Metabolic Health in Thyroid Cancer Survivors: Clinical Implicationshttps://reachmd.com/news/mediterranean-diet-and-metabolic-health-in-thyroid-cancer-survivors-clinical-implications/2484267/In a study published in Nutrients on patients with papillary thyroid cancer, adherence to the Mediterranean diet at diagnosis was associated with improved metabolic markers within one
- Fresenius Medical Care Showcases Innovations at ASN Kidney Week 2025https://reachmd.com/news/fresenius-medical-care-showcases-innovations-at-asn-kidney-week-2025/2484257/Fresenius Medical Care will present ASN Kidney Week 2025 data showing high-volume hemodiafiltration (HDF) is associated with fewer cardiovascular- and fluid-related hospitalizations and will unveil AI tools to support safe implementation, according to the
- Assessing IV Thrombolysis Before EVT in Basilar Artery Occlusions: A Comprehensive Pooled Analysishttps://reachmd.com/news/assessing-iv-thrombolysis-before-evt-in-basilar-artery-occlusions-a-comprehensive-pooled-analysis/2484261/A pooled patient-level analysis of four randomized trials finds no significant difference in 90‑day functional outcomes when IV thrombolysis is given before endovascular thro